F605 in Oklahoma. Pick another state for the same tag.
Against expectation — 2025
Oklahoma cites F605 more often than its own record predicts
Versus expected share1.94×
1.94 times the share F605 takes of citations nationally.
Share of Oklahoma citations1.37%
Of every deficiency written in Oklahoma in 2025, this is the portion that was F605.
Oklahoma1.37%
National0.70%
Share of all citations that were F605.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What Oklahoma surveyors wrote
F605 findings written in Oklahoma, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
D · No harm, potential for more than minimal, isolatedAugust 27, 2026
Based on record review and interview, the facility failed to ensure psychotropic medication was discontinued as ordered for 1 (#30) of 5 sampled residents reviewed for unnecessary psychotropic medications. The administrator identified 29 residents received psychotropic medications in the facility. Findings:A physician's order for Resident #30, dated 08/25/26, showed to administer lorazepam (Ativan) (anti-anxiety medication) 0.5 mg daily for anxiety disorder. GDR documentation, dated 11/17/25, showed lorazepam (Ativan) 0.5 mg daily to be discontinued. …
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction